Abstract:While medicinal inorganic chemistry has been practised for over 5000 years, it was not until the late 1800s when Alfred Werner published his ground-breaking research on coordination chemistry that we began to truly understand the nature of the coordination bond and the structures and stereochemistries of metal complexes. We can now readily manipulate and fine-tune their properties. This had led to a multitude of complexes with wide-ranging biomedical applications. This review will focus on the use and potential of metal complexes as important therapeutic agents for the treatment of cancer. With major advances in technologies and a deeper understanding of the human genome, we are now in a strong position to more fully understand carcinogenesis at a molecular level. We can now also rationally design and develop drug molecules that can either selectively enhance or disrupt key biological processes and, in doing so, optimize their therapeutic potential. This has heralded a new era in drug design in which we are moving from a single- toward a multitargeted approach. This approach lies at the very heart of medicinal inorganic chemistry. In this review, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new families of metallodrugs which may not only reduce systemic toxicities associated with modern day chemotherapeutics but also address resistance issues that are plaguing many chemotherapeutic regimens. We have focused our attention on metallodrugs incorporating platinum and ruthenium ions given that complexes containing these metal ions are already in clinical use or have advanced to clinical trials as anticancer agents. The "multitargeted" complexes described herein not only target DNA but also contain either vectors to enable them to target cancer cells selectively and/or moieties that target enzymes, peptides, and intracellular proteins. Multitargeted complexes which have been designed to target the mitochondria or complexes inspired by natural product activity are also described. A summary of advances in this field over the past decade or so will be provided.

Multi-Target Metal-Based Anticancer Agents

Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

Metal-based Anticancer Chemotherapeutic Agents.

New Strategies and Trends for the Design of Metal-Based Anticancer Drugs

Metal-N-heterocyclic carbene complexes as anti-tumor agents

Research Progress of Metal Anticancer Drugs

Biomedical applications of multinuclear Pt(II)/Ru(II)/Ir(III) metallo-supramolecular assemblies for intensive cancer therapy

Towards the Rational Design of Platinum(ii) and Gold(iii) Complexes As Antitumour Agents

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Engineering Metal Nanoclusters for Targeted Therapeutics: From Targeting Strategies to Therapeutic Applications

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship

Metallo-Drugs in Cancer Therapy: Past, Present and Future

Metal nanoparticles as a promising technology in targeted cancer treatment

Recent Advances of Platinum-Based Anticancer Complexes in Combinational Multimodal Therapy

Anticancer agents based on metal organic cages

Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance

Metal Complexes of Natural Product Like-compounds with Antitumor Activity.

Research progress of natural product-conjugated platinum and gold complexes as potential antitumor agents

Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses.

A Multifaceted Approach Towards Organometallic Anticancer Agent Development

Supramolecular Delivery Systems for Non-Platinum Metal-Based Anticancer Drugs